Intervention timing and disease stage shape tecovirimat and cidofovir efficacy in male SCID mice
Xinyu Cao, Ning Shi, Xiangshu Qiu, Jiaxin Tian, Peng Wang, Bocheng Liu, Zhuo Ha, He Zhang, Chao Shang, Xiao Li, Yubiao Xie, Yuelong Shu, Huijun Lu · 2025
Read Intervention timing and disease stage shape tecovirimat and cidofovir efficacy in male SCID mice by Xinyu Cao, Ning Shi, Xiangshu Qiu, Jiaxin Tian, Peng Wang, Bocheng Liu, Zhuo Ha, He Zhang, Chao Shang, Xiao Li, Yubiao Xie, Yuelong Shu, Huijun Lu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12827245.txt.
Description
Xinyu Cao and co-authors test two antiviral drugs against mpox in mice in a 2025 study. The virus remains a global health challenge, and people with weak immune systems often suffer worse illness. The team first screened three male mouse models and chose SCID mice, which lack key immune defenses, as the best match for severe disease.
Both drugs, tecovirimat and cidofovir, stopped the virus from spreading through the body when given within two days of exposure. Their local effects differed, especially after infection through the skin. Treatment extended to twenty-eight days gave full survival but failed to suppress local rash and swelling well. The authors conclude that timing and disease stage shape how well these drugs work.
Catalog record
| CREATOR | Xinyu Cao, Ning Shi, Xiangshu Qiu, Jiaxin Tian, Peng Wang, Bocheng Liu, Zhuo Ha, He Zhang, Chao Shang, Xiao Li, Yubiao Xie, Yuelong Shu, Huijun Lu |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |